Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Can Immunopeptidomics Redefine Cancer Immunotherapy Development?
Immunopeptidomics is helping researchers identify tumor-presented antigens that could inform the development of targeted cell therapies and personalized cancer vaccines
Clinical Scorecard: Can Immunopeptidomics Redefine Cancer Immunotherapy Development?
At a Glance
Category
Detail
Condition
Cancer immunotherapy development, including research in pancreatic ductal adenocarcinoma (PDAC)
Key Mechanisms
Immunopeptidomics profiles antigenic peptides displayed by MHC molecules using immunoaffinity purification, LC-MS/MS, and bioinformatics; it can identify tumor-specific, spliced, modified, and cryptic peptides.
Target Population
Research and development focused on tumor antigens and immunotherapies, including CAR-T cell therapies and personalized cancer vaccines
Care Setting
Translational oncology research and immunotherapy development; the article does not describe a clinical care setting.
Key Highlights
Immunopeptidomics profiles antigenic peptides presented by tumor and antigen-presenting cells using LC-MS/MS.
In PDAC research, immunopeptidomics can help identify novel T-cell targets and tumor-specific antigens, including spliced, post-translationally modified, and cryptic peptides.
The article describes IDA/DDA as providing high-confidence fragmentation spectra for selected precursors and DIA as offering broader coverage and improved reproducibility across replicates.
The article describes tunable EAD as a method for resolving peptide isomers, including leucine/isoleucine and aspartate/isoaspartate, while preserving labile modifications.
Immunopeptidomics findings may inform CAR-T target selection and peptide-based vaccine development.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
The article describes analytical challenges in detecting and characterizing diverse HLA-bound peptides, including modified peptides and sequence isomers.
PDAC’s immunosuppressive tumor microenvironment poses challenges for CAR-T therapies.
Patient & Prescribing Data
No patient-level prescribing or treatment data are provided; the article focuses on research and analytical methods.
Immunopeptidomics findings may inform the design of CAR-T therapies and personalized peptide-based vaccines; no dosing or prescribing guidance is provided.
Clinical Best Practices
The article describes workflows combining immunoaffinity purification, high-resolution LC-MS/MS, and bioinformatics to characterize HLA-bound peptides.
The article describes IDA/DDA for high-confidence spectra of selected precursors and DIA for broader coverage and reproducibility.
The article describes EAD for investigating structural isomers and labile modifications, and targeted MRM for validating and quantifying selected tumor-specific antigens.
